ライフサイエンスコーパス: coeliac

1 ctive Crohn's, treated coeliac and untreated coeliac.

2 tential to mitigate the problems confronting coeliacs.

3 ts were stratified by adenopathy (no vs yes [coeliac absent] vs yes [coeliac present <=2 cm]) and ran

4 duced by subdiaphragmatic or by coeliac plus coeliac accessory branch vagotomy.

5 erent activity is carried in the coeliac and coeliac accessory branches of the subdiaphragmatic vagus

6 e results indicate that afferent activity in coeliac and accessory coeliac vagal branches is involved

7 is vagal afferent activity is carried in the coeliac and coeliac accessory branches of the subdiaphra

8 measurements in screening and monitoring of coeliac and Crohn's disease is promising.

9 s aims to determine LMR in healthy subjects, coeliac and Crohn's disease.

10 In patch-clamp studies, nodose, coeliac and superior cervical ganglia (SCG) neurones fro

11 gh spinal intermediolateral neurons and both coeliac and sympathetic chain ganglia.

12 s, inactive Crohn's, active Crohn's, treated coeliac and untreated coeliac.

13 e wheat flour and develop bread suitable for coeliacs and gluten intolerant individuals.

14 CI: 0.740 to 1.984, p < 0.001), (3) treated coeliacs and untreated coeliacs (SMD = 0.722 95% CI: 0.2

15 of the descending aorta at the level of the coeliac arteries, a stimulus that elevated blood pressur

16 and a study involving members of the Swedish Coeliac Association with 1031 adult participants.

17 (i) Interruption of the coeliac branches mimicked the effect of total subdiaphra

18 Glossodynia on GFD was more prevalent in the coeliac cohort than in the controls (14% vs 6%, p < 0.00

19 re more common among patients than among non-coeliac controls (27% vs. 4%, p < 0.001).

20 lt patients with coeliac disease and 563 non-coeliac controls.

21 subsets that may be safely incorporated into coeliac diets.

22 RD0.1), Urticaria (1.58[1.57-1.60], RD1.9), Coeliac disease (1.42[1.37-1.47], RD0.1), Ulcerative col

23 ad positive antibody results, of whom 14 had coeliac disease (11 EMA positive, three EMA negative).

24 The largest increases were seen in coeliac disease (2.19 [2.05-2.35]), Sjogren's syndrome (

25 son's disease (IRR 26.5 [95% CI 17.3-40.7]), coeliac disease (28.4 [25.2-32.0]), and thyroid disease

26 ildren with IgE-mediated wheat allergy (WA), coeliac disease (CD) and Helicobacter pylori infection (

27 The consequences of subclinical coeliac disease (CD) in Type 1 diabetes mellitus (T1DM)

28 Coeliac disease (CD) is an inflammatory autoimmune disea

29 Coeliac disease (CD) is characterised by diverse clinica

30 studies have shown that the knowledge about coeliac disease (CD) is not satisfactory among healthcar

31 -endopeptidase treatment may not be safe for coeliac disease (CD) patients.

32 Coeliac disease (CD), an enteropathy caused by cereal gl

33 for proteins with epitopes that can trigger coeliac disease (CD), and several contain a 33-mer pepti

34 Coeliac disease (CD), due to its protean clinical manife

35 Despite the considerable health impact of coeliac disease (CD), reliable estimates of the impact o

36 o a gluten-free diet (GFD) for patients with coeliac disease (CD).

37 s been proposed to play a pathogenic role in coeliac disease (CD).

38 ed by several clinical conditions, including Coeliac Disease (CD).

39 ant microbiota may play a pathogenic role in coeliac disease (CD).

40 loci shared between two autoimmune diseases: coeliac disease (CeD) and rheumatoid arthritis (RA).

41 Coeliac disease (CeD) is an autoimmune disease in which

42 Coeliac disease (CeD) is characterized by gliadin-induce

43 such as inflammatory bowel disease (IBD) and coeliac disease (CeD).

44 systemic sclerosis (OR 1.60, 1.29-2.22), and coeliac disease (OR 1.38, 1.12-1.69).

45 systemic sclerosis (OR 3.20, 2.21-4.53) and coeliac disease (OR 1.71, 1.36-2.14).

46 l syndrome was significantly associated with coeliac disease (p=0.004, odds ratio=7.0 [95% CI 1.7-28.

47 osed with active CD, CD on a GFD, Refractory coeliac disease (RCD) type I and II, and enteropathy ass

48 A strong HLA association is seen in coeliac disease [specifically to the DQ(alpha1*0501,beta

49 based study involved 873 adult patients with coeliac disease and 563 non-coeliac controls.

50 nity including thyroiditis, type 1 diabetes, coeliac disease and alopecia areata(1,2).

51 lude the association of Down's syndrome with coeliac disease and Alzheimer's disease, and improved me

52 enes at HLA-unlinked loci also predispose to coeliac disease and are probably stronger determinants o

53 develop biomarkers of small bowel damage in coeliac disease and Crohn's disease.

54 rker of small bowel damage, in children with coeliac disease and Crohn's disease.

55 nded to occur rapidly after the diagnosis of coeliac disease and cumulative survival dropped in the f

56 dietary gluten intake in conditions such as coeliac disease and dermatitis herpetiformis.

57 ersensitivity (FHS), including food allergy, coeliac disease and food intolerance, is a major public

58 falls of vitamin A supplementation in active coeliac disease and have enabled identification of oat a

59 untries experienced: poor dietary intake for coeliac disease and inflammatory bowel disease, cultural

60 ng, the well established association between coeliac disease and insulin dependent diabetes mellitus,

61 ptibility to type 1 diabetes (T1D) with both Coeliac disease and multiple sclerosis.

62 isk to people affected by conditions such as coeliac disease and non-coeliac gluten sensitivity.

63 understanding of the complex pathogenesis of coeliac disease and novel therapeutic targets.

64 tic susceptibilities that are both unique to coeliac disease and overlap with other autoimmune diseas

65 mall bowel Crohn's disease, complications of coeliac disease and surveillance of polyposis syndromes.

66 e the possible concealed burden of untreated coeliac disease and the effects of a gluten-free diet.

67 especially regarding the natural history of coeliac disease and the effects on long-term health for

68 sidue at position beta57 are associated with coeliac disease and type I diabetes.

69 5-positive patients aged 18-70 years who had coeliac disease and were on a gluten-free diet.

70 NCWS individuals, in whom coeliac disease and wheat allergy were ruled out, receiv

71 learned about the mechanisms of MS by using coeliac disease as a model.

72 designed for the selective amplification of coeliac disease associated alleles (DQA1*05, DQB1*02, DQ

73 ies against tissue transglutaminase (marking coeliac disease autoimmunity) also appeared early (2-4 y

74 l criterion to compare duodenal histology in coeliac disease before and after gluten withdrawal.

75 Crohn's disease and coeliac disease both demonstrate considerable overlap in

76 gliadin antibodies are a marker of untreated coeliac disease but can also be found in individuals wit

77 eurological syndromes may be associated with coeliac disease but it is unclear whether these are dire

78 (age and sex matched) were investigated for coeliac disease by analysis of serum IgA antigliadin, Ig

79 Although coeliac disease can be misdiagnosed as irritable bowel s

80 gnosis, and a low QALY score for undiagnosed coeliac disease cases.

81 The number of people diagnosed with coeliac disease continues to rise, and this article crit

82 y of the mechanism of the immune response in coeliac disease could provide insight into the mechanism

83 Coeliac disease develops in genetically susceptible indi

84 Prior to the coeliac disease diagnosis, 56% of the patients had exper

85 resence of abdominal symptoms at the time of coeliac disease diagnosis, long diagnostic delay and fem

86 The long-term implications of active coeliac disease emphasize the need for early detection a

87 breed bread wheat varieties with fewer or no coeliac disease epitopes.

88 We have examined these regions in 28 coeliac disease families by linkage analysis.

89 iopsy did not identify any causes other than coeliac disease for iron deficiency anaemia, suggesting

90 astrointestinal symptom rating scale (GSRS), coeliac disease GSRS, and Bristol stool form scale (BSFS

91 as lost, at which point 25% of patients with coeliac disease had detectable gluten in faeces, whilst

92 in developing new strategies for preventing coeliac disease has motivated efforts to identify cereal

93 manifestations in patients with established coeliac disease have been reported since 1966, it was no

94 Notably, IEL from patients with Coeliac disease have high PIM expression.

95 in two patients, and changes compatible with coeliac disease in 11.

96 Worldwide awareness of coeliac disease in all ages continues to grow.

97 barley and rye, or gluten protein, can cause coeliac disease in individuals not tolerating gluten.

98 g offers additional sensitivity in detecting coeliac disease in individuals who have self-prescribed

99 a measure of cryptic gluten sensitivity, and coeliac disease in neurological patients.

100 om group 1 revealed histological evidence of coeliac disease in nine (35%), non-specific duodenitis i

101 candidate locus conferring susceptibility to coeliac disease in some families.

102 Coeliac disease is a common enteropathy characterized by

103 Coeliac disease is a complex, polygenic inflammatory ent

104 Coeliac disease is a genetically-determined chronic infl

105 Currently, the only effective treatment for coeliac disease is a lifelong strict gluten-free diet; h

106 The diagnosis of coeliac disease is achieved by combining coeliac disease

107 Coeliac disease is also considered to be a systemic diso

108 Coeliac disease is an autoimmune disorder that primarily

109 Complicated coeliac disease is an extremely serious condition with a

110 Coeliac disease is an immune-mediated enteropathy agains

111 Epidemiological studies have shown that coeliac disease is as common in parts of Asia, Africa an

112 Undiagnosed coeliac disease is associated with a substantial decreme

113 Coeliac disease is caused by a genetically determined, s

114 The natural history of complicated coeliac disease is characterised by two different types

115 Coeliac disease is characterised by villous atrophy, whi

116 Living with undiagnosed symptomatic coeliac disease is connected with deteriorated health, a

117 sentation, diagnosis remains a challenge and coeliac disease is heavily underdiagnosed.

118 Clinical presentation of coeliac disease is highly variable and includes classica

119 ease, but further work into the treatment of coeliac disease is needed.

120 Coeliac disease is the prototypical gluten-sensitive dis

121 Epidemiological studies have shown that coeliac disease is very common and affects about one in

122 e molecular basis for the HLA association in coeliac disease is well defined, and B cells have a clea

123 was to determine the cost-effectiveness of a coeliac disease mass screening at 12 years of age, takin

124 A coeliac disease mass screening is cost-effective based o

125 ion is difficult because occult sub-clinical coeliac disease occurs commonly and background prevalenc

126 Coeliac disease occurs in about 1% of people in most pop

127 d with deteriorated health, and persons with coeliac disease often wait a long time for their diagnos

128 macodynamics of the vaccine in patients with coeliac disease on a gluten-free diet.

129 with cerebellar ataxia and SG diagnosed with coeliac disease or gluten sensitivity, 15% had RFC1 expa

130 ased or wheat-based foods, in the absence of coeliac disease or wheat allergy.

131 gate these issues in a large cohort of adult coeliac disease patients both at diagnosis and while on

132 d messenger RNA (mRNA) expression changes in coeliac disease patients challenged with gluten using PA

133 ficant duodenal mucosal deterioration in all coeliac disease patients on gluten challenge.

134 In our material, 8/245 (3,2 %) coeliac disease patients presented inflammatory bowel di

135 Evidence suggests that many coeliac disease patients suffer from persistent clinical

136 Fifteen coeliac disease patients were challenged with 4 g of glu

137 a cytokine greatly upregulated in the gut of coeliac disease patients, retinoic acid rapidly activate

138 Patients with established coeliac disease referred for neurological opinion show s

139 - 13 years (range 19-64)) with biopsy proven coeliac disease referred for neurological opinion.

140 Our findings on coeliac disease replicate the previous SNP results and s

141 Diagnosis of coeliac disease requires a positive serology (IgA anti-t

142 Optimizing diagnosis and care in coeliac disease requires continuous research and educati

143 The cost for coeliac disease screening was 40,105 Euro per gained QAL

144 of coeliac disease is achieved by combining coeliac disease serology and small intestinal mucosal hi

145 Coeliac disease serology was positive in all cases.

146 cts on long-term health for individuals with coeliac disease still eating gluten.

147 Before diagnosis, people with coeliac disease suffer reduced quality of life, which im

148 to assess changes over time in prevalence of coeliac disease symptoms/associated medical conditions,

149 was higher in patients with newly diagnosed coeliac disease than Controls (median [Q1, Q3] coeliac d

150 t, at diagnosis and on GFD, in patients with coeliac disease than in the controls, and they were asso

151 of course: patients with a new diagnosis of coeliac disease that do not improve despite a strict glu

152 Although the evidence for linkage of coeliac disease to chromosome 15q26 is not strong, the w

153 ee diet, rapid progression from symptom-free coeliac disease to coeliac disease with symptoms, long d

154 Refractory coeliac disease type 2 is a rare subtype of coeliac dise

155 In patients with refractory coeliac disease type 2 who were treated with AMG 714 or

156 lts with a confirmed diagnosis of refractory coeliac disease type 2.

157 may be warranted in patients with refractory coeliac disease type 2.

158 , on the activity and symptoms of refractory coeliac disease type 2.

159 after 12 weeks of treatment in patients with coeliac disease undergoing gluten challenge, was not sig

160 Coeliac disease was associated with excessive health car

161 In 7/8 patients the diagnosis of coeliac disease was made first and inflammatory bowel di

162 significant evidence in favour of linkage to coeliac disease was obtained for chromosomes 3q27, 5q33.

163 gical dysfunction is a known complication of coeliac disease we have investigated the frequency of an

164 gate the effects of AMG 714 in patients with coeliac disease who underwent gluten challenge.

165 coeliac disease type 2 is a rare subtype of coeliac disease with high mortality rates; interleukin 1

166 We aimed to assess the association of coeliac disease with irritable bowel syndrome in patient

167 ression from symptom-free coeliac disease to coeliac disease with symptoms, long delay from celiac di

168 in our understanding of the pathogenesis of coeliac disease(4), the respective roles of disease-pred

169 orwegian Human Milk Study, and Prevention of Coeliac Disease) that collaborate in the European Union-

170 e meta-analysis measured gut permeability in coeliac disease, 17 studies in Crohn's disease.

171 opsy samples from 42 patients with untreated coeliac disease, 37 treated patients, and 18 controls, w

172 gluten-free diet is the only means to manage coeliac disease, a permanent immune intolerance to glute

173 ren participated and 240 were diagnosed with coeliac disease, and a study involving members of the Sw

174 ed age 18-80 years, a confirmed diagnosis of coeliac disease, and adherence to a gluten-free diet for

175 d urine of children with ulcerative colitis, coeliac disease, and Crohn's disease at diagnosis and fr

176 tunity to both increase our understanding of coeliac disease, and develop new therapeutic strategies.

177 icanus larvae for allergic rhinitis, asthma, coeliac disease, and multiple sclerosis.

178 or all immune recognition of wheat gluten in coeliac disease, and to explore if the tissue transgluta

179 ases such as systemic lupus erythematosus or coeliac disease, antibodies to specific membrane targets

180 esis and improving diagnostic strategies for coeliac disease, but further work into the treatment of

181 s have mainly been studied: Turner syndrome, coeliac disease, cystic fibrosis, growth hormone deficie

182 -related extra-intestinal diseases including coeliac disease, diabetes mellitus type 1, bronchial ast

183 n our genetic and immunological knowledge of coeliac disease, early introduction of a gluten-free die

184 ore, similar to the involvement of gluten in coeliac disease, Epstein-Barr virus (EBV) infection is n

185 ina propria that is characteristic of active coeliac disease, expresses the predisposing HLA-DQ8 mole

186 ociated with systemic lupus erythematosus or coeliac disease, have not in general disclosed consisten

187 erstanding of inflammatory bowel disease and coeliac disease, hindered by language and literacy barri

188 nded our knowledge of the long-term risks of coeliac disease, in addition to excluding infertility as

189 Within our cohort of patients with coeliac disease, inflammatory bowel disease was signific

190 testinal and endocrine diseases, focusing on coeliac disease, inflammatory bowel disease, diabetes, a

191 Coeliac disease, or gluten-sensitive enteropathy, is onl

192 and sent to 4000 individuals with diagnosed coeliac disease, requesting information on respondents'

193 present in cereal proteins that do not cause coeliac disease, Shan and colleagues suggest that genera

194 data, clinical presentation and treatment of coeliac disease, time and place of diagnosis and presenc

195 Conditions such as coeliac disease, type 1 diabetes, Crohn's disease and ul

196 diseases including asthma, Crohn's disease, coeliac disease, vitiligo, multiple sclerosis and type 1

197 A notable exception is coeliac disease, where genetically susceptible individua

198 ultiple sclerosis (MS) is similar to that of coeliac disease, with human leukocyte antigen (HLA) bein

199 time and place of diagnosis and presence of coeliac disease-associated or other co-morbidities.

200 Coeliac disease-related data were collected from medical

201 central role of IL-15 in the pathogenesis of coeliac disease.

202 in resolving long-lasting health problems in coeliac disease.

203 a burdensome life-long gluten-free diet for coeliac disease.

204 sed symptoms and impaired quality of life in coeliac disease.

205 dditional primary care costs associated with coeliac disease.

206 proximately 1% of the population suffer from coeliac disease.

207 gnostic approach to reduce underdiagnosis of coeliac disease.

208 e recent scientific and clinical advances in coeliac disease.

209 e critically the recent research advances in coeliac disease.

210 onhuman leucocyte antigen genetic factors in coeliac disease.

211 help improve quality of life of people with coeliac disease.

212 he molecular pathways involving cytokines in coeliac disease.

213 tive gluten peptides presented by HLA-DQ8 in coeliac disease.

214 mune system is central to the development of coeliac disease.

215 sponsiveness, and tissue transglutaminase in coeliac disease.

216 3) known to induce small intestine damage in coeliac disease.

217 P kinase might have the potential to control coeliac disease.

218 an adaptive immune response in patients with coeliac disease.

219 ents with this disorder are investigated for coeliac disease.

220 ry care should be investigated routinely for coeliac disease.

221 ontrols, both of whom were EMA positive, had coeliac disease.

222 uodenal biopsy to confirm the possibility of coeliac disease.

223 the commonest neurological manifestation of coeliac disease.

224 ily history of inflammatory bowel disease or coeliac disease.

225 -15) is implicated in the pathophysiology of coeliac disease.

226 urrent aphthous ulcerations in patients with coeliac disease.

227 ion and markedly ameliorate the pathology of coeliac disease.

228 bowel disease, irritable bowel syndrome, and coeliac disease.

229 elial stress, which has been associated with Coeliac disease.

230 that is analogous to the gluten-free diet in coeliac disease.

231 ent of pathologies such as food allergies or coeliac disease.

232 be warranted in patients with non-responsive coeliac disease.

233 to gluten-challenge studies of patients with coeliac disease.

234 body to be investigated for the treatment of coeliac disease.

235 rapeutic vaccine, Nexvax2, designed to treat coeliac disease.

236 nt of this potential therapeutic vaccine for coeliac disease.

237 l biopsy for those tested positive to detect coeliac disease.

238 ology found no causes for anaemia other than coeliac disease.

239 first months after diagnosis of complicated coeliac disease.

240 eliac disease than Controls (median [Q1, Q3] coeliac disease: 2104 pg/mL 1493, 2457] vs Controls: 938

241 re), 58% a TSH dosage (7%) and 8% a test for coeliac diseases (1%) and the year after: 44% (8%), 43%

242 selected members of the Swedish Society for Coeliacs, divided into equal-sized age- and sex strata;

243 The development of the coeliac enteropathy depends on a complex immune response

244 nosis and presence of thyroidal disease, non-coeliac food intolerance or gastrointestinal co-morbidit

245 in isolated superior cervical ganglia (SCG), coeliac ganglia (CG), and superior mesenteric ganglia (S

246 sympathetic neurons acutely dissociated from coeliac ganglia of the guinea-pig.

247 Neurones from mouse aortic-renal and coeliac ganglia were identified as either 'tonic' or 'ph

248 Truncal vagotomy or treatment of the coeliac ganglia with capsaicin did not significantly aff

249 Truncal vagotomy or treatment of the coeliac ganglia with capsaicin did not significantly aff

250 DiI crystals were placed bilaterally on the coeliac ganglia, labeled piriform and fusiform pregangli

251 dominal sympathetic (mesenteric) nerves, the coeliac ganglia, or on the rostral three somatic spinal

252 in parallel to disease progression, whereas coeliac ganglionectomy led to the disintegration of adve

253 Non-coeliac gluten sensitivity (NCGS) is still a poorly defi

254 Non-coeliac gluten sensitivity (NCGS) refers to individuals

255 y conditions such as coeliac disease and non-coeliac gluten sensitivity.

256 be a potential alternative for reduction of coeliac immunological activities in gluten proteins.

257 tomach (nucleus gelatinosus); 5) hepatic and coeliac nerves (nucleus subpostrema); and 6) carotid bod

258 se-specific mortality compared to those with coeliac node metastasis (HR 0.71, 95% CI 0.40-1.27).

259 It is uncertain whether coeliac node metastasis precludes long-term survival in

260 patients with distal oesophageal cancer with coeliac node metastasis seem to have a similarly poor su

261 The prognosis in patients with coeliac node metastasis was compared with patients with

262 Among 446 patients, 346 (77.6%) had no coeliac node metastasis, 56 (12.6%) had coeliac node met

263 d no coeliac node metastasis, 56 (12.6%) had coeliac node metastasis, and 44 (9.9%) had more distant

264 Compared to coeliac node negative patients, coeliac node positive pa

265 Compared to coeliac node negative patients, coeliac node positive patients were at a 52% increased r

266 y iFABP did not differ between patients with coeliac on GFD and Controls.

267 uidance to identify studies assessing LMR in coeliac or Crohn's disease.

268 Siblings of coeliac patients carry a high risk, but those found to h

269 g of gluten per day for 10 weeks and 24 non-coeliac patients served as disease controls.

270 diet (type A cases) and previously diagnosed coeliac patients that initially improved on a gluten-fre

271 Untreated coeliac patients used primary health care services more

272 ationwide cohort of 700 newly detected adult coeliac patients were prospectively evaluated.

273 Duodenal biopsies from coeliac patients were retrospectively reviewed to compar

274 Clinical and laboratory data from coeliac patients who later developed complications (A an

275 ons (A and B cases) and sex- and age-matched coeliac patients who normally responded to a gluten-free

276 Introduction of a gluten-free diet improves coeliac patients' quality of life.

277 arsh-Oberhuber class worsened in only 80% of coeliac patients.

278 s health concerns in long-term treated adult coeliac patients.

279 nhibition produced by subdiaphragmatic or by coeliac plus coeliac accessory branch vagotomy.

280 how unequivocally that: (a) receptors in the coeliac-portal circulation are more sensitive in amplify

281 enopathy (no vs yes [coeliac absent] vs yes [coeliac present <=2 cm]) and randomly assigned (1:1) to

282 diet remains paramount as the recognition of coeliac related complications increases.

283 ties and cost effectiveness of pre-endoscopy coeliac screening with Simtomax in anaemia; 3) whether o

284 high risk, but those found to have negative coeliac serology are very unlikely to develop the diseas

285 International guidelines recommend coeliac serology in iron deficiency anaemia, and duodena

286 blood count and C-reactive protein, negative coeliac serology, and no evidence of suicidal ideation.

287 MR between: (1) healthy controls and treated coeliacs (SMD = 0.409 95% CI 0.034 to 0.783, p = 0.032),

288 < 0.001), (3) treated coeliacs and untreated coeliacs (SMD = 0.722 95% CI: 0.286 to 1.157, p = 0.001)

289 = 0.032), (2) healthy controls and untreated coeliacs (SMD = 1.362 95% CI: 0.740 to 1.984, p < 0.001)

290 he study included 2500 members of the Polish Coeliac Society.

291 ical, stellate, paravertebral chain ganglia, coeliac/superior mesenteric and inferior mesenteric gang

292 aled that the mean time between the onset of coeliac symptoms and being diagnosed was above 13 years.

293 Resected arterial segments included the coeliac trunk (50), hepatic artery (29), superior mesent

294 ere also obtained across the aorta above the coeliac trunk, superior mesenteric vein, splenic vein an

295 ositive in 8/9 first-degree relatives having coeliac-type mucosal lesions of grade Marsh 2 (n = 3) or

296 t afferent activity in coeliac and accessory coeliac vagal branches is involved in the regulation of

297 Coeliac vagal nerve activation increases splenic sympath

298 ents were activated: splenic sympathetic and coeliac vagus nerve activities increased in parallel to

299 ) while pooled LMRs in untreated and treated coeliac were 0.133 (95% CI: 0.089-0.178) and 0.037 (95%

300 n help improve the total dietary intake of a coeliac while not negating on the quality properties of